Back to All Resources

Discovery of a First-In-Class MDM2 Degrader for the Treatment of Relapsed/Refractory TP-53 Wt AML & Solid Tumors

October 27, 2022

5th Annual Targeted Protein Degradation (TPD) Summit

MDM2
View Presentation
Area of Focus
Oncology
Programs
MDM2 (KT-253)
Indications
Liquid Tumors Solid Tumors
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link

You may also be interested in these resources

December 11, 2022
Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the treatment of Acute Myeloid Leukemia
American Society of Hematology Annual Meeting
Liquid Tumors
View Resource
October 14, 2023
The MDM2 degrader KTX-049 is highly potent in TP53 wild-type (p53 WT) Merkel cell carcinoma (MCC)
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Solid Tumors
View Resource
June 6, 2023
Pulse Dosing of Potent and Selective Heterobifunctional MDM2 Degrader KT-253 Drives Tumor Regression and Demonstrates Differentiated Pharmacology Compared to p53/MDM2 Small Molecule Inhibitors
European Hematology Association (EHA) 2023 Hybrid Congress
Liquid Tumors
View Resource